COMPLETEDPHASE2

Glycine Treatment of Prodromal Symptoms

NCT00268749•Yale University

Summary

This is an open label trial of the NMDA agonist glycine used alone for symptoms that appear to be prodromal for schizophrenia in adolescents and young adults.

Eligibility

Age

14 - 35 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•age 14-35
•meets SIPS criteria for psychosis prodrome

Exclusion Criteria

•current antipsychotic medication
•more than 4 weeks of antipsychotic medication lifetime

Key Dates

Start Date

July 1, 2002

Primary Completion Date

November 1, 2004

Completion Date

November 1, 2004

Last Updated

March 29, 2012

Enrollment

10

ACTUAL participants

Conditions

Schizophrenia

Interventions

glycine

DRUG

Feasibility, Acceptability, and Preliminary Efficacy of Yoga-based Group Intervention for Outpatients With Schizophrenia Spectrum Disorders

NCT07455929

Psychotic DisordersSchizophrenia Spectrum Disorders

View study

RECRUITING

Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services

NCT06740383

Schizophrenia Spectrum and Other Psychotic DisordersSchizophrenia+5 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 29, 2012Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

RECRUITINGPHASE2